-
公开(公告)号：US20200339974A1
公开(公告)日：2020-10-29
申请号：US16487745
申请日：2018-02-22
Applicant: Cancer Research Technology Ltd.
Inventor： Gregory Hannon , Clare Rebbeck , Simon Knott
Abstract: The present invention provides a method for targeted cell retrieval, comprising: providing a population of barcoded cells, said population comprising a plurality of different barcodes, each of the plurality of different barcodes being uniquely targetable with a target-specific CRISPR RNA; introducing a CRISPR-Cas system, or one or more vectors encoding the components of the CRISPR-Cas system, into the population of barcoded cells said CRISPR-Cas system having a target-specific CRISPR RNA that targets a first barcode of said plurality of different barcodes, thereby causing a CRISPR-Cas system-mediated change at a target site leading to a change in one or more detectable properties of at least one cell carrying said first barcode; and retrieving said at least one cell carrying said first barcode based on the change in said one or more detectable properties. Also provided are products and kits for use in the method of the invention.
-
公开(公告)号：US20190241671A1
公开(公告)日：2019-08-08
申请号：US16126296
申请日：2018-09-10
Applicant: CANCER RESEARCH TECHNOLOGY LTD.
Inventor： Michael Super , Jonathan Davis , Pascal Andre Stein
IPC: C07K16/30 , A61K39/395 , C07K16/28
CPC classification number: C07K16/30 , A61K39/3955 , A61K2039/505 , C07K16/2803 , C07K16/2866 , C07K16/2896 , C07K2317/24 , C07K2317/41 , C07K2317/56 , C07K2317/567 , C07K2317/732 , A61K2300/00
Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
-
公开(公告)号：US20190194166A1
公开(公告)日：2019-06-27
申请号：US16309121
申请日：2017-06-13
Applicant: GlaxoSmithKline Intellectual Property Development Limited , Cancer Research Technology Ltd.
Inventor： Nicholas David ADAMS , Andrew B. BENOWITZ , María Lourdes Rueda BENEDE , Karen Anderson EVANS , David T. FOSBENNER , Bryan Wayne KING , Mei LI , Juan Ignacio LUENGO , William Henry MILLER , Alexander Joseph REIF , Stuart Paul ROMERIL , Stanley J. SCHMIDT , Roger J. BUTLIN , Kristen M. GOLDBERG , Allan M. JORDAN , Christopher S. KERSHAW , Ali RAOOF , Bohdan WASZKOWYCS
IPC: C07D401/12 , C07D417/12 , A61P35/00 , A61P37/00
CPC classification number: C07D401/12 , A61P35/00 , A61P37/00 , C07D213/73 , C07D213/74 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/12
Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof.The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
-
公开(公告)号：US10261099B2
公开(公告)日：2019-04-16
申请号：US14823755
申请日：2015-08-11
Applicant: Cancer Research Technology Ltd.
Inventor： Frances Balkwill , Violet Slettenaar , Julia Wilson , Yaohe Wang , Tiziana Schioppa
IPC: A61K31/00 , C07K16/28 , G01N33/50 , G01N33/74 , G01N33/574
Abstract: Chemokine receptor CCR4 and its ligands CCL17 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL17 and CCL22 provide anti-cancer agents.
-
公开(公告)号：US20160223572A1
公开(公告)日：2016-08-04
申请号：US14823755
申请日：2015-08-11
Applicant: Cancer Research Technology Ltd.
Inventor： Frances Balkwill , Violet Slettenaar , Julia Wilson , Yaohe Wang , Tiziana Schioppa
IPC: G01N33/74 , G01N33/574 , C07K16/28
CPC classification number: G01N33/74 , A61K31/00 , C07K16/2866 , G01N33/5005 , G01N33/574 , G01N33/57492 , G01N2333/726 , G01N2800/52 , G01N2800/56
Abstract: Chemokine receptor CCR4 and its ligands CCL17 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL17 and CCL22 provide anti-cancer agents.
Abstract translation: 趋化因子受体CCR4及其配体CCL17和CCL22用作癌症鉴定和/或分期的标志物。 发现CCR4，CCL17和CCL22的水平在恶性肿瘤进展期间增加。 CCR4，CCL17和CCL22根据其对抗癌剂治疗的适用性，用作癌症患者分层的标记物。 通过测量患者样本中存在的CCR4，CCL17和CCL22中的一个或多个的水平来提供诊断特征的信息。 癌症患者治疗CCR4，CCL17和CCL22活性调节剂的方法。 筛选调节CCR4，CCL17和CCL22的生物活性的试剂的方法提供抗癌剂。
-
Patent Agency Ranking
公开(公告)号：US11208496B2
公开(公告)日：2021-12-28
申请号：US16126296
申请日：2018-09-10
Applicant: CANCER RESEARCH TECHNOLOGY LTD.
Inventor： Michael Super , Jonathan Davis , Pascal Andre Stein
Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
-
公开(公告)号：US20170362314A1
公开(公告)日：2017-12-21
申请号：US15535976
申请日：2015-12-11
Applicant: Cancer Research Technology LTD
Inventor： Frances Rosemary Balkwill , John McCafferty , Gerard John Graham , Aneesh Karatt Vellatt , Peter Slavny
CPC classification number: C07K16/24 , A61K39/00 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N15/66
Abstract: Anti-CXCL12 antibody molecules and their uses are disclosed, and in particular anti-CXCL12 antibody molecules that are capable of inhibiting a biological activity of CXCL12 in vitro and in vivo and their use for treating CXCL12-mediated disease.
-
公开(公告)号：US20160041187A1
公开(公告)日：2016-02-11
申请号：US14782929
申请日：2014-04-09
Applicant: CANCER RESEARCH TECHNOLOGY LTD
Inventor： Frances BALKWILL , Chiara BERLATO , Laura FLETCHER
CPC classification number: G01N33/6863 , A61K2039/505 , C07K16/40 , G01N33/57484 , G01N2333/521 , G01N2333/523 , G01N2800/52 , G01N2800/56 , G01N2800/7028
Abstract: The present invention provides methods of obtaining information relevant to monitoring and diagnosing cancer, particularly monitoring the progression or development of cancer, monitoring the response of cancer to treatment, diagnosing cancer, making a cancer prognosis, predicting the likelihood of a cancer responding to treatment and stratifying subjects having cancer. The methods involve determining the ratio of circulating CCL17 to circulating CCL22 in a sample from a subject.
Abstract translation: 本发明提供了获得与监测和诊断癌症有关的信息的方法，特别是监测癌症的进展或发展，监测癌症对治疗的响应，诊断癌症，制定癌症预后，预测癌症对治疗的响应的可能性以及 分层患有癌症的受试者。 该方法涉及确定来自受试者的样品中循环CCL17与循环CCL22的比例。
-
9.发明申请NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS 审中-公开新型萘啶和异喹啉及其作为CDK8 / 19抑制剂的用途公开(公告)号：US20160016951A1
公开(公告)日：2016-01-21
申请号：US14802042
申请日：2015-07-17
Applicant: Merck Patent GmbH , Cancer Research Technology, Ltd.
Inventor： Kai SCHIEMANN , Julian BLAGG , Aurelie MALLINGER , Christian RINK , Jimmy SEJBERG , Mark HONEY
IPC: C07D471/04 , C07D401/12 , C07D417/14 , C07D401/14 , C07D413/14 , C07D401/10
CPC classification number: C07D471/04 , C07D217/22 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D413/14 , C07D417/04 , C07D417/14
Abstract: The present invention relates to naphthyridine and isoquinoline compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of CDK8/19, and for the treatment of CDK8/19-related disorders.
Abstract translation: 本发明涉及可用作CDK8 / 19抑制剂和用于治疗CDK8 / 19相关疾病的萘啶和异喹啉化合物及其药学上可接受的组合物。
-
公开(公告)号：US10975056B2
公开(公告)日：2021-04-13
申请号：US16309121
申请日：2017-06-13
Applicant: GlaxoSmithKline Intellectual Property Development Limited , Cancer Research Technology Ltd.
Inventor： Nicholas David Adams , Andrew B. Benowitz , María Lourdes Rueda Benede , Karen Anderson Evans , David T Fosbenner , Bryan Wayne King , Mei Li , Juan Ignacio Luengo , William Henry Miller , Alexander Joseph Reif , Stuart Paul Romeril , Stanley J. Schmidt , Roger J. Butlin , Kristin M. Goldberg , Allan M. Jordan , Christopher S. Kershaw , Ali Raoof , Bohdan Waszkowycz
IPC: C07D401/12 , C07D401/04 , C07D213/73 , C07D213/74 , C07D413/14 , C07D417/12 , A61P37/00 , A61P35/00 , C07D401/14
Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.044 seconds)
